TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data

IASLC Journals Share Exciting Milestones on Metrics Journeys

In Brief for Oct. 26, 2022

In Brief for Nov. 9, 2022

In Brief for Dec. 21, 2022